Twenty leading medical and legal experts, and seven peak health and community services organisations, will send today an open letter to John Howard and Mark Latham demanding changes to the free trade agreement with the US before the agreement is ratified in late October.
El investigador y académico argentino sostiene que en materia de propiedad intelectual Estados Unidos quiere más de lo que consagran los acuerdos internacionales de la OMC. Si Colombia, Ecuador y Perú ceden ante esas peticiones correrán un grave riesgo, asegura.
Los países en desarrollo han participado en un gran número de tratados bilaterales de inversión (TBI), así como en acuerdos de libre comercio (ALC) que incluyen obligaciones explícitas de proteger los derechos de la propiedad intelectual por ser considerados como “inversiones”.
US Trade Representative Robert Zoellick’s warning to Australia that an amended free-trade agreement might conflict with the letter and spirit of the original agreement was prompted by bullying from the American pharmaceuticals industry, according to a US trade adviser.
Tariffs on agricultural products and definitions of intellectual property rights, particularly for pharmaceuticals, are shaping up as the most contentious issues in the free trade negotiations between the United States and three Andean nations, Colombia, Ecuador, and Peru.
El colombiano Germán Velásquez dice que fue injusto el veto de EE.UU. contra el asesor argentino Carlos Correa. Sostiene que los países pobres deben seguir teniendo acceso a las medicinas baratas así haya tratados comerciales. Pide que se respete el Acuerdo de Doha.
Australia’s ratification of a free trade agreement with the United States has sparked warnings that it represents a major win for the U.S. drug industry in blocking generic manufacturers and undermining the country’s internationally acclaimed system for lowering pharmaceutical prices.
The funny thing about the free trade agreement with the United States is that Australians and Americans see it as being about completely different things. Australia’s businesspeople see it as about eliminating the barriers to exports and imports between the two countries, which they regard as a good thing.
Kerryn Williams spoke to David Henry, clinical pharmacology professor at Newcastle University and former Pharmaceutical Benefits Advisory Committee member, about how the proposed US-Australia Free Trade Agreement will undermine the Pharmaceutical Benefits Scheme, and increase the price of medicine.
Developing countries have entered into a large number of bilateral investment treaties (BITs) as well as free trade agreements (FTAs) that include explicit obligations for the protection of intellectual property rights as "investments".
A long-awaited Australia-US free trade agreement (FTA) hit a new snag in Canberra, just hours after US President George W. Bush reaffirmed Washington’s commitment to a pact he called "a milestone in the history of our alliance".
Welcome to the brave new world of “Free” Trade. This is a world that extends beyond the World Trade Organisation. This may be difficult to comprehend, but the fact of the matter is that global capital, led by the US government, seeks more and more to tread where even the WTO did not.
If Howard and Bush’s so-called ’free trade’ deal is confirmed by the Australian parliament and senate (WHICH CAN ONLY HAPPEN IF THE ALP VOTES WITH THE GOVERNMENT), genetically engineered crops and foods will be forced down our throats and onto our farms, and our hopes for GE-free Australia will end!!
The government lied when it said it would exclude medicines from the list of products included under the prospective freetrade agreement between Thailand and the United States, a seminar was told yesterday.
The Medical Journal of Australia, published by the Australian Medical Association, this week carries two articles claiming the free trade agreement (FTA) will undermine the Pharmaceutical Benefits Scheme (PBS).
Bilateral trade treaties have hit stormy waters in recent weeks, drawing criticism from French President Jacques Chirac, a leading world economist and human rights groups alike.
The reason for President Museveni’s renewed vigour to support US ideologies in the battle against HIV/Aids is becoming clearer after Bangkok, Thailand.
As public-health groups urge wider use of generic drugs to lower the cost of treating AIDS and other diseases in developing countries, U.S. trade negotiators — prodded by the drug industry — are taking the opposite stance in new trade pacts, seeking to strengthen protections for costlier brand-name drugs.
The US and France clashed on Tuesday over allegations by President Jacques Chirac that Washington was seeking to use bilateral trade agreements to reduce developing countries’ access to cheap medicines for diseases such as HIV/Aids.
DNP+ and MSF Access Campaign India have set up a blog about the ongoing negotiations of a number of multi- and bilateral free trade agreements, which harm the access to essential medicines.
HAI (Health Action International) Europe and HAI Latin America have formed an alliance to monitor and lobby negotiations on Association Agreements between the EU and the countries of the Andean region on Intellectual Property Rights demanded by the EU which are likely to have a negative effect on Access to Essential Medicines.
A submission to the Australian Senate Select Committee on the US-Australia Free Trade Agreement by Prof Peter Drahos, Dr Thomas Faunce, Martyn Goddard and
Prof David Henry (May 2004)